DOPA
|
Basic information |
| Metabolite name | DOPA |
 | HMDB0000181 |
 |
C00355 |
 |
6047 |
| Synonyms | Dihydroxyphenylalanine; |
| No. of studies | 23 |
|
Basic information |
| Metabolite name | DOPA |
| HMDB0000181 |
|
C00355 |
|
6047 |
| Synonyms | Dihydroxyphenylalanine; |
| No. of studies | 23 |
|
Relationship between DOPA and depression (count: 23) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M011 | Type4 | placebo-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Up |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M091 | Type1 | CSDS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Prefrontal cortex | Wistar rat | Up |
| Study M1091 | Type1 | CMS vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1092 | Type1 | CMS group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1092 | Type3 | venlafaxine group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1105 | Type1 | psychological stress group vs. control group | Faece | C57BL/6 J mouse | Down |
| Study M1142 | Type2 | MDD group, after intermittent theta burst stimulation vs. baseline | Plasma | Human | Up |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M516 | Type1 | SMG-treated group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M581 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M581 | Type2 | CUMS + high dose of S. chinensis group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M583 | Type1 | PSD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Down |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M651 | Type1 | LPS group vs. control group | Brain | C57BL/6 mouse | Down |
| Study M651 | Type2 | LPS + fish oil group vs. LPS group | Brain | C57BL/6 mouse | Up |
| Study M672 | Type1 | SMG group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M672 | Type2 | SMG + Hemerocallis citrina extracts group vs. SMG group | Urine | Sprague-Dawley rat | Up |
| Study M672 | Type2 | SMG + paroxetine group vs. SMG group | Urine | Sprague-Dawley rat | Up |
| Study M720 | Type1 | CUMS susceptible group vs. control group | Habenula | Sprague-Dawley rat | Down |
| Study M766 | Type1 | CUS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M827 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M827 | Type1 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M827 | Type1 | CUMS + middle dose of Millettia speciosa Champ group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M867 | Type2 | CUMS + Baihe-Dihuang Tang group vs. CUMS group | Urine | Sprague-Dawley rat | Unknown |